The combination of ATR, Chk1 and DNA‐PK inhibitors with doxorubicin or cyclophosphamide demonstrates synergistic toxicities in DLBCL cells in association with DNA damage, inhibition of proliferation and apoptosis induction. Here, ATR is linked to diffuse large B-cell lymphoma.